|
prIME Oncology invites you to view prIME Downloadable Slides that focus on new breast cancer data just released from the 2010 CTRC-AACR San Antonio Breast Cancer Symposium.
prIME Downloadable Slides from the 2010 CTRC-AACR San Antonio Breast Cancer Symposium.
|
|
|
 |
|
This slide deck covers the topic of advanced breast cancer, focusing on the following data releases:
Abstract #S1-3: A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the ‘FIRST’ study
Abstract #S1-6: TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI)
Abstract #S3-5: Discordance in hormone receptor and HER2 status in breast cancer during tumor progression
Abstract #PD05-01: CALGB 40302: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study
|
 |
|
This slide deck covers the topic of prognostic/predictive tools for breast cancer, focusing on the following data releases:
Abstract #S1-2: ACOSOG Z1031: A randomized neoadjuvant comparison between letrozole (LET), anastrozole (ANA) and exemestane (EXE) for postmenopausal women with ER Rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype
Abstract #S4-9: Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score
Abstract #S5-1: Prospective outcomes for patients with micro-metastases and macro-metastases in sentinel nodes: NSABP B-32 sentinel node trial
Abstract #S5-5: Identification of a clinically relevant gene signature in triple negative and basal like breast cancer
|
 |
|
This slide deck covers the topic of early breast cancer, focusing on the following data releases:
Abstract #S4-1: FinXX final 5-year analysis: Results of the randomised, open label, phase III trial in medium-to-high risk early breast cancer
Abstract #S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide followed by docetaxel with or without capecitabine in high-risk early breast cancer
Abstract #S4-5: Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE Trial (BIG 01/04)
Abstract #S4-6: Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)
|
 |
|
This slide deck covers the topic of early HER2-positive breast cancer, focusing on the following data releases:
Abstract #S3-1: Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44)
Abstract #S3-2: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (‘NeoSphere’)
Abstract #S3-3: First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III , randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancer
|
 |
|
This slide deck covers the topic of endocrine-responsive breast cancer, focusing on the following data releases:
Abstract #S1-1: Final analysis of NCIC CTG MA.27: A randomized phase II trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer
Abstract #S1-8: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial
Abstract #S2-1: Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer
Abstract #S2-6: Aromatase inhibitors and risk of myocardial infarction, stroke and fracture
|
|
|
